logo
ProjectEnded

Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Goal is the clinical validation of a new peritoneal dialysis (PD) system called CORDIAL. Instead of a stagnant filling as in traditional PD, CORDIAL continuously circulates and regenerates dialysate in the peritoneal cavity. Hereby, a significant improvement in blood purification (2-3x) can be achieved in comparison to traditional PD. For the regeneration, a sorbent unit is used to remove toxins f

Status
Closed
Sector
Water Supply and Storage, Residential, Government
Location
Netherlands
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration” is an infrastructure initiative in the Water Supply and Storage sector, located in Netherlands, Italy, Spain, United Kingdom. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Sponsoring Agency

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Goal is the clinical validation of a new peritoneal dialysis (PD) system called CORDIAL. Instead of a stagnant filling as in traditional PD, CORDIAL continuously circulates and regenerates dialysate in the peritoneal cavity. Hereby, a significant improvement in blood purification (2-3x) can be achieved in comparison to traditional PD. For the regeneration, a sorbent unit is used to remove toxins from the peritoneal dialysate by adsorption. The sorbent system also facilitates slow release of glucose needed for osmotic removal of excess fluid (i.e. ultrafiltration). Very high glucose concentrations, as used in traditional PD and harmful to the peritoneal membrane, are no longer required, which helps to preserve the membrane function. CORDIAL is an easy to use, portable/wearable machine that allows renal patients to dialyze conveniently at home or at work, independently from a fixed water supply, up to 24 h/day. With the improved clearance and low glucose load, CORDIAL eliminates current drawbacks of PD (low efficacy, high glucose concentrations leading to damage to the peritoneal membrane), benefiting the overall health condition and quality of life (fitness, lower pill burden). In order to demonstrate clinical efficacy and safety of the system an early feasibility first-in-human (FIH) trial will be performed in PD patients. The FIH study will involve a group of 12 stable PD patients who will be treated for 6 days with the new PD system spread over two weeks (3 consecutive days per week), which will be compared with baseline measurements in the week prior and after CORDIAL treatment. In addition, an advanced computational model will be developed and validated for CORDIAL using the FIH data, which can be used to conduct virtual human trials for rapid optimization of device settings/ design and personalization of the treatment.

Location

Country

Netherlands

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Water Supply and Storage, Residential, Government

Article published date

2025-10-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project